Enspryng

Описание товара

About Enspryng

Enspryng is a medicine that contains the active substance satralizumab.

How it is used

Treatment with Enspryng should be started under the supervision of a doctor experienced in treating NMOSD. The medicine can only be obtained with a prescription. Enspryng is available as a solution in a prefilled syringe to be injected under the skin of the abdomen (belly) or the thigh. Treatment starts with one injection every two weeks for the first three injections and continues with one injection every four weeks after that. Patients or their caregivers can inject Enspryng themselves after training by a healthcare professional. Vaccinations should be up to date and any infection should be well controlled before starting treatment with Enspryng. Patients should also be monitored for infection during treatment with Enspryng.

How it works

The active substance in Enspryng, satralizumab, is a monoclonal antibody, a type of protein that has been designed to block the action of interleukin-6 (IL-6), a protein in the body involved in the production of antibodies against AQP4. By blocking IL-6, the medicine decreases the production of antibodies against AQP4 and therefore assures the activity of AQP4. This should prevent damage to nerve cells and reduce the symptoms of NMOSD.

Active substance: satralizumab

Source: EMA EPAR